Assessing the Complexity of a Recovered Design and its Potential Redesign Alternatives

Organised by: Cranfield UniversityReverse engineering techniques are applied to generate a part model where there is no existing documentation or it is no longer up to date. To facilitate the reverse engineering tasks, a modular, multiperspective design recovery framework has been developed. An evaluation of the product and feature complexity characteristics can readily be extracted from the design recovery framework by using a modification of a rapid complexity assessment tool. The results from this tool provide insight with respect to the original design and assists with the evaluation of potential alternatives and risks, as illustrated by the case study.Mori Seiki – The Machine Tool Compan

A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer.

Metastatic non-small cell lung cancer (NSCLC) carries a dismal prognosis. Clinical evidence suggests the existence of an intermediate, or oligometastatic, state when metastases are limited in number and/or location. In addition, following initial curative therapy, many patients present with limited metastatic disease, or oligo-recurrence. Metastasis-directed, anti-cancer therapies may benefit these patients. A growing evidence-base supports the use of hypofractionated, image-guided radiotherapy (HIGRT) for a variety of malignant conditions including inoperable stage I NSCLC and many metastatic sites. When surgical resection is not possible, HIGRT offers an effective alternative for local treatment of limited metastatic disease. Early studies have produced promising results when HIGRT was delivered to all known sites of disease in patients with oligometastatic/oligo-recurrent NSCLC. In a population of patients formerly considered rapidly terminal, these studies report five year overall survival rates of 13-22%. HIGRT for metastatic NSCLC warrants further study. We call for large, intergroup, and even international randomized trials incorporating HIGRT and other metastasis-directed therapies into the treatment of patients with oligometastatic/oligo-recurrent NSCLC